Innovation

Based in Beijing, Shanghai, Guangzhou and Princeton, US, our global clinical development and regulatory teams have extensive knowledge and experience. Concurrently, we leverage the efficient regulatory approval pathway to accelerate the Investigational New Drug (IND) applications and early-phase clinical trials in the United States and to advance clinical trials in the indications with significant unmet medical needs from the large patient population in China.